ペプチド薬物複合体 (PDC)：市場洞察・競合情勢・市場予測 (～2032年)

ペプチド薬物複合体 (PDC) の市場規模は、2024年の19億2,751万米ドルから、予測期間中はCAGR 28.73％で推移し、2032年には138億4,985万米ドルの規模に成長すると予測されています。

世界の癌患者の増加は、従来の治療と比較して有効性が向上し、全身毒性が軽減された標的治療薬としてのペプチド薬物複合体 (PDC) の需要を大きく促進しています。優れた治療効果、生体適合性、特定の腫瘍細胞を標的とする能力により、PDCの採用が増加していることが、市場の成長をさらに加速しています。さらに、バイオテクノロジー企業、研究機関、製薬企業間の戦略的提携の増加がイノベーションを促進し、新規PDCの開発を促進しています。現在進行中の製品開発活動は、ペプチド合成技術やコンジュゲーション技術の進歩と相まって、PDCの治療用途を拡大し、2025年から2032年までの予測期間中の世界のPDC市場を総合的に押し上げる見通しです。

ペプチド薬物複合体 (PDC) の市場力学：

国際癌研究機関 (International Agency for Research on Cancer) が提供した最近のデータ (2024年) によると、2022年に世界で新たに発生した前立腺癌の推定症例数は147万人で、2045年には263万人に増加すると予測されています。前立腺特異的膜抗原 (PSMA) と結合するように設計されたものなど、前立腺癌を標的とするPDCは、正常組織を温存しながら癌細胞に直接細胞傷害性薬剤を送達することで、治療精度を著しく向上させます。この標的アプローチは毒性を軽減し、治療効果を高めます。また、PDCは腫瘍抗原提示を促進することで免疫反応を刺激し、抗癌作用を高めることができます。さらに、ペプチド合成技術やコンジュゲーション技術への投資の増加や技術の進歩が、次世代PDCの開発を促進し、前立腺癌に対する有望な治療法となり、前立腺癌におけるPDC市場の成長を後押ししています。

さらに、同じ情報源によると、2022年におけるホジキンリンパ腫や非ホジキンリンパ腫などの血液悪性腫瘍の推定新規患者数は、それぞれ82,500人と553,000人であり、2045年にはそれぞれ10,900人と890,000人に達すると予測されています。多くのリンパ腫はCD19やCD20のような特異的な表面マーカーを発現しており、それらはペプチドによって標的とすることができます。これらのペプチドに細胞傷害性薬剤を結合させることで、PDCは悪性細胞に直接薬剤を送達することができ、健康な組織へのダメージを抑えながら治療効果を高めることができるため、PDCの市場を押し上げることになります。

製品別では、Lutathera (lutetium Lu 177 dotatate) が2024年に37%の市場シェアで市場を独占すると推定されています。Lutatheraは、標的癌治療、特に神経内分泌腫瘍 (NET) に対する画期的な役割により、PDC市場全体を大きく牽引しています。FDAが初めて承認した放射性同位元素標識ソマトスタチン類似体として、ソマトスタチン受容体陽性腫瘍を標的とする卓越した有効性を実証しており、その能力は癌治療において際立っています。Lutatheraの主な利点の一つは、標的放射線を照射する能力であり、従来の化学療法によく見られる副作用を軽減します。ルタセラは、ソマトスタチン受容体を発現する腫瘍細胞に特異的に結合することで、正常組織へのダメージを最小限に抑え、患者の予後と生活の質を改善することができます。

地域別では、北米が2024年に56.70%の最大シェアを占め、予測期間中は28.47%のCAGRで成長すると予測されています。PDC開発のための主要企業間の協力関係の増加や、PDCの領域における新興国市場の発展が、この地域のPDC市場全体をさらに押し上げています。

当レポートでは、世界のペプチド薬物複合体 (PDC) の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 ペプチド薬物複合体 (PDC) 市場レポート：イントロダクション

• 調査範囲
• 市場セグメンテーション
• 市場の前提因子

第2章 ペプチド薬物複合体 (PDC) 市場：エグゼクティブサマリー

• 市場概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 ペプチド薬物複合体 (PDC) 市場：主要要因分析

• 市場促進要因
  • 世界中で癌の症例が増加
  • 優れた治療結果と有効性の向上によりペプチド薬物治療の採用が増加
  • PDC分野における戦略的コラボレーションと製品開発活動の増加
• 市場抑制要因と課題
  • 固形腫瘍に対する治療効果の限定性と経口バイオアベイラビリティの低さ
  • 製造コストの高さと複雑さ
• 市場機会
  • PDCのパイプラインでの強力な医薬品ポートフォリオの存在

第6章 ペプチド薬物複合体 (PDC) 市場：ポーターのファイブフォース分析

第7章 ペプチド薬物複合体 (PDC) 市場の評価

• 製品別
  • Lutathera (lutetium Lu 177 dotatate)
  • Lutathera (Melphalan flufenamide)
  • Pluvicto (Melphalan flufenamide)
• 癌タイプ別
  • 前立腺癌
  • 消化器癌
  • 多発性骨髄腫
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 ペプチド薬物複合体 (PDC) 市場：企業・製品プロファイル

• Novartis AG
• Oncopeptides AB
• Cybrexa Therapeutics
• Avacta Therapeutics
• ProteinQure
• Theratechnologies Inc.
• CBP
• Soricimed Biopharma
• NMS Group S.p.A.
• Mainline Scientific LLC.
• Bicycle Therapeutics

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項・問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Peptide Drug Conjugates Market in Global (2022-2032)
• Table 3: Peptide Drug Conjugates Market in Global by Product (2022-2032)
• Table 4: Peptide Drug Conjugates Market in Global by Cancer Type (2022-2032)
• Table 5: Peptide Drug Conjugates Market in Global by Geography (2022-2032)
• Table 6: Peptide Drug Conjugates Market in North America (2022-2032)
• Table 7: Peptide Drug Conjugates Market in the United States (2022-2032)
• Table 8: Peptide Drug Conjugates Market in Canada (2022-2032)
• Table 9: Peptide Drug Conjugates Market in Mexico (2022-2032)
• Table 10: Peptide Drug Conjugates Market in Europe (2022-2032)
• Table 11: Peptide Drug Conjugates Market in France (2022-2032)
• Table 12: Peptide Drug Conjugates Market in Germany (2022-2032)
• Table 13: Peptide Drug Conjugates Market in the United Kingdom (2022-2032)
• Table 14: Peptide Drug Conjugates Market in Italy (2022-2032)
• Table 15: Peptide Drug Conjugates Market in Spain (2022-2032)
• Table 16: Peptide Drug Conjugates Market in the Rest of Europe (2022-2032)
• Table 17: Peptide Drug Conjugates Market in Asia-Pacific (2022-2032)
• Table 18: Peptide Drug Conjugates Market in China (2022-2032)
• Table 19: Peptide Drug Conjugates Market in Japan (2022-2032)
• Table 20: Peptide Drug Conjugates Market in India (2022-2032)
• Table 21: Peptide Drug Conjugates Market in Australia (2022-2032)
• Table 22: Peptide Drug Conjugates Market in South Korea (2022-2032)
• Table 23: Peptide Drug Conjugates Market in Rest of Asia-Pacific (2022-2032)
• Table 24: Peptide Drug Conjugates Market in the Rest of the World (2022-2032)
• Table 25: Peptide Drug Conjugates Market in the Middle East (2022-2032)
• Table 26: Peptide Drug Conjugates Market in Africa (2022-2032)
• Table 27: Peptide Drug Conjugates Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Peptide Drug Conjugates Market in Global (2022-2032)
• Figure 3: Peptide Drug Conjugates Market in Global by Product (2022-2032)
• Figure 4: Peptide Drug Conjugates Market in Global by Cancer Type (2022-2032)
• Figure 5: Peptide Drug Conjugates Market in Global by Geography (2022-2032)
• Figure 6: Peptide Drug Conjugates Market in North America (2022-2032)
• Figure 7: Peptide Drug Conjugates Market in the United States (2022-2032)
• Figure 8: Peptide Drug Conjugates Market in Canada (2022-2032)
• Figure 9: Peptide Drug Conjugates Market in Mexico (2022-2032)
• Figure 10: Peptide Drug Conjugates Market in Europe (2022-2032)
• Figure 11: Peptide Drug Conjugates Market in France (2022-2032)
• Figure 12: Peptide Drug Conjugates Market in Germany (2022-2032)
• Figure 13: Peptide Drug Conjugates Market in the United Kingdom (2022-2032)
• Figure 14: Peptide Drug Conjugates Market in Italy (2022-2032)
• Figure 15: Peptide Drug Conjugates Market in Spain (2022-2032)
• Figure 16: Peptide Drug Conjugates Market in the Rest of Europe (2022-2032)
• Figure 17: Peptide Drug Conjugates Market in Asia-Pacific (2022-2032)
• Figure 18: Peptide Drug Conjugates Market in China (2022-2032)
• Figure 19: Peptide Drug Conjugates Market in Japan (2022-2032)
• Figure 20: Peptide Drug Conjugates Market in India (2022-2032)
• Figure 21: Peptide Drug Conjugates Market in Australia (2022-2032)
• Figure 22: Peptide Drug Conjugates Market in South Korea (2022-2032)
• Figure 23: Peptide Drug Conjugates Market in Rest of Asia-Pacific (2022-2032)
• Figure 24: Peptide Drug Conjugates Market in the Rest of the World (2022-2032)
• Figure 25: Peptide Drug Conjugates Market in the Middle East (2022-2032)
• Figure 26: Peptide Drug Conjugates Market in Africa (2022-2032)
• Figure 27: Peptide Drug Conjugates Market in South America (2022-2032)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Market Opportunities
• Figure 31: PORTER'S Five Force Analysis

Peptide Drug Conjugates Market by Product (Lutathera (lutetium Lu 177 dotatate), Pepaxti (Melphalan flufenamide), and Pluvicto (lutetium Lu 177 vipivotide tetraxetan)), Cancer Type (Prostate Cancer, Gastrointestinal Cancer, Multiple Myeloma), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising cases of cancer worldwide, growing adoption of peptide drug therapeutics owing to superior treatment outcomes and enhanced efficacy, and increase in strategic collaborations and product development activities in the domain of peptide drug conjugates across the globe.

The Peptide Drug Conjugates market was valued at USD 1,927.51 million in 2024, growing at a CAGR of 28.73% during the forecast period from 2025 to 2032 to reach USD 13,849.85 million by 2032. The rising cases of cancer worldwide are significantly driving the demand for Peptide Drug Conjugates (PDCs) as targeted therapies, offering enhanced efficacy and reduced systemic toxicity compared to traditional treatments. The growing adoption of peptide drug therapeutics, owing to their superior treatment outcomes, biocompatibility, and ability to target specific tumor cells, further accelerates market growth. Additionally, increased strategic collaborations between biotech companies, research institutions, and pharmaceutical firms are fostering innovation and expediting the development of novel PDCs. Ongoing product development activities, coupled with advancements in peptide synthesis and conjugation technologies, are expanding the therapeutic applications of PDCs, and collectively boosting the global peptide drug conjugate market during the forecast period from 2025 to 2032.

Peptide Drug Conjugates Market Dynamics:

As per the recent data provided by the International Agency for Research on Cancer (2024), in 2022, globally, the estimated number of new cases of prostate cancer was 1.47 million and the projections were estimated to increase to 2.63 million by 2045. Peptide-drug conjugates, targeting prostate cancer, such as those designed to bind prostate-specific membrane antigen (PSMA), significantly enhance treatment precision by delivering cytotoxic agents directly to cancer cells while sparing normal tissues. This targeted approach reduces toxicity and boosts therapeutic outcomes. Additionally, PDCs can stimulate an immune response by promoting tumor antigen presentation, enhancing their anti-cancer effects. Additionally, increasing pharmaceutical investments and advancements in peptide synthesis and conjugation technologies are driving the development of next-generation PDCs, making them a promising therapy for prostate cancer, and thereby boosting the market growth for peptide drug conjugates in prostate cancer.

Additionally, as per the same source, globally, the estimated new cases of hematological malignancies such as Hodgkin lymphoma and non-Hodgkin lymphoma in 2022 were 82,500 and 553,000 respectively and the projections were indicated to reach 10,900 and 890,000 respectively by 2045. Many lymphomas express specific surface markers, such as CD19 and CD20, which can be targeted by peptides. By conjugating cytotoxic agents to these peptides, PDCs can deliver drugs directly to malignant cells, enhancing therapeutic efficacy while reducing damage to healthy tissues and hence boosting the market of PDCs.

However, the increased adoption and superior treatment outcomes with enhanced efficacy of peptide drug conjugates are driving their adoption as promising therapeutic options in oncology. By leveraging the specificity of peptides for targeted delivery, PDCs improve drug accumulation at tumor sites while minimizing systemic toxicity. For instance, a recent study developed a HER2-targeting peptide-drug conjugate (HER2-TPMC) that demonstrated superior specificity and lower cytotoxicity compared to traditional chemotherapeutic agents like mertansine. The smaller size of HER2-TPMC enables rapid tissue penetration and effective tumor uptake, resulting in better therapeutic outcomes.

For instance, in March 2024, ProteinQure, the leading startup in the computational design of peptide drugs, announced a significant breakthrough in the fight against triple-negative breast cancer (TNBC). The novel Peptide Drug Conjugate (PDC) designed by ProteinQure demonstrated exceptional efficacy in a comprehensive suite of Patient-Derived Xenograft (PDX) models.

Thus, the factors mentioned above are expected to boost the overall market of peptide drug conjugates across the globe during the forecast period from 2025 to 2032.

However, limited therapeutic potential on solid tumors low oral bioavailability, and high manufacturing costs and complexity may hinder the future market of peptide drug conjugates across the globe during the forecasted period.

Peptide Drug Conjugates Market Segment Analysis:

Peptide Drug Conjugates Market by Product (Lutathera (lutetium Lu 177 dotatate), Pepaxti (Melphalan flufenamide), and Pluvicto (lutetium Lu 177 vipivotide tetraxetan)), Cancer Type (Prostate Cancer, Gastrointestinal Cancer, Multiple Myeloma), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The Lutathera (lutetium Lu 177 dotatate) category in the peptide drug conjugates market is estimated to dominate the market with a market share of 37% in 2024. Lutathera is significantly driving the overall market for peptide drug conjugates due to its groundbreaking role in targeted cancer therapy, particularly for neuroendocrine tumors (NETs). As the first FDA-approved radiolabeled somatostatin analog, it has demonstrated exceptional efficacy in targeting somatostatin receptor-positive tumors, a capability that sets it apart in the oncology treatment landscape. One of the key advantages of Lutathera is its ability to deliver targeted radiation, reducing the side effects commonly associated with traditional chemotherapy. By binding specifically to tumor cells expressing somatostatin receptors, Lutathera minimizes damage to normal tissues, which can improve patient outcomes and quality of life.

Furthermore, Lutathera has set a precedent in the growing field of peptide receptor radionuclide therapy (PRRT), sparking further interest in developing other peptide drug conjugates for the treatment of various cancers. For instance, in April 2024, Novartis announced that the FDA approved Lutathera(R) (lutetium Lu 177 dotatate) for treating pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), making it the first therapy approved for pediatric GEP-NETs.

Thus, its success demonstrates the potential of radiopharmaceuticals in targeted therapy and is encouraging to drive continued investment in innovative treatments that combine peptides with radioactive agents for better precision in cancer treatment.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of peptide drug conjugates across the globe.

North America is expected to dominate the overall peptide drug conjugates market:

Among all regions, North America is estimated to hold the largest share of 56.70% in the global peptide drug conjugates market in 2024, growing at a CAGR of 28.47% during the forecast period from 2025 to 2032. This can be attributed to the rising cases of cancer in the U.S. Additionally, the increase in collaborations among key players for peptide drug conjugates development, and growing investments in the domain of PDCs are further propelling the overall market of PDCs across the region.

According to the American Cancer Society 2024, nearly 2 million new cancer cases are expected to be diagnosed in the United States by the end of 2024, up from 1.9 million in 2023.

As per the Centers for Disease Control and Prevention (2024), the U.S. cancer statistics recorded 1,777,566 new cases of invasive cancer occurring in 2021; comprising 272,454 breast cancers, 141,902 colorectal cancers, and 209,500 lung cancers reported in 2021. As cancer cases rise, there is a growing demand for innovative therapies that effectively target tumor cells while sparing healthy tissues. PDCs address this need by combining peptides with potent cytotoxic agents, enhancing treatment efficacy and minimizing systemic toxicity.

Additionally, key players in the region are focusing on R&D to develop innovative peptide-drug conjugates. For example, in February 2021, Theratechnologies Inc. announced that the U.S. Food and Drug Administration (FDA) had granted fast-track designation for TH1902, a docetaxel-based peptide-drug conjugate, as a monotherapy aimed at treating patients with sortilin-positive recurrent advanced solid tumors resistant to standard therapies.

Moreover, in April 2024, Novartis, with its two marketed PDC drugs approved by the FDA, collaborated with PeptiDream to expand its peptide drug conjugate development collaboration in a deal valued at more than USD 2.8 billion.

Thus, the above-mentioned factors are expected to escalate the market of peptide drug conjugates in the region.

Peptide Drug Conjugates Market Key Players:

Some of the key market players operating in the peptide drug conjugates market include Novartis AG, Oncopeptides AB, Cybrexa Therapeutics, Avacta Therapeutics, ProteinQure, Theratechnologies Inc., CBP, Soricimed Biopharma, NMS Group S.p.A., Mainline Scientific LLC., Bicycle Therapeutics, and others.

Recent Developmental Activities in the Peptide Drug Conjugates Market:

• In April 2024, PeptiDream Inc. announced the expansion of its peptide discovery collaboration with Novartis Pharma AG. Using its proprietary Peptide Discovery Platform System (PDPS(R)), PeptiDream identified and optimized macrocyclic peptides for conjugation with radionuclides for therapeutic and diagnostic applications.
• In March 2023, Ono Pharmaceutical Co., Ltd. announced that it entered into a drug discovery collaboration agreement with PeptiDream Inc., to discover and develop novel macrocyclic constrained peptide drugs against multiple targets of Ono's interest.
• In December 2022, PeptiDream Inc. announced that it entered into a Research Collaboration and License Agreement with U.S.-based Eli Lilly and Company. The agreement focused on the discovery and development of novel peptide drug conjugates (PDCs). This collaboration aimed to leverage PeptiDream's advanced peptide discovery technologies to develop innovative PDC therapies.

Key Takeaways From the Peptide Drug Conjugates Market Report Study

• Market size analysis for current peptide drug conjugates size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the peptide drug conjugates market.
• Various opportunities are available for the other competitors in the peptide drug conjugates market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current peptide drug conjugates market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for peptide drug conjugates market growth in the coming future?

Target Audience Who Can be Benefited From This Peptide Drug Conjugates Market Report Study

• Peptide drug conjugates product providers
• Research organizations and consulting companies
• Peptide drug conjugates -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in peptide drug conjugates
• Various end-users who want to know more about the peptide drug conjugates market and the latest technological developments in the peptide drug conjugate market.

Frequently Asked Questions for the Peptide Drug Conjugates Market:

1. What are peptide drug conjugates?

• Peptide-drug conjugates (PDCs) are an innovative class of targeted therapeutics designed for precise drug delivery, particularly in cancer treatment. They consist of three key components: a peptide, a linker, and a cytotoxic or radioactive drug. The peptide, a short amino acid sequence, selectively binds to specific receptors on target cells, enabling enhanced tissue penetration and targeted delivery.

2. What is the market for peptide drug conjugates?

• The Peptide Drug Conjugates market was valued at USD 1,927.51 million in 2024, growing at a CAGR of 28.73% during the forecast period from 2025 to 2032 to reach USD 13,849.85 million by 2032.

3. What are the drivers for the global peptide drug conjugates market?

• The rising cases of cancer worldwide are significantly driving the demand for Peptide Drug Conjugates (PDCs) as targeted therapies, offering enhanced efficacy and reduced systemic toxicity compared to traditional treatments. The growing adoption of peptide drug therapeutics, owing to their superior treatment outcomes, biocompatibility, and ability to target specific tumor cells, further accelerates market growth. Additionally, increased strategic collaborations between biotech companies, research institutions, and pharmaceutical firms are fostering innovation and expediting the development of novel PDCs. Ongoing product development activities, coupled with advancements in peptide synthesis and conjugation technologies, are expanding the therapeutic applications of PDCs, and collectively boosting the global peptide drug conjugate market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global peptide drug conjugates market?

• Some of the key market players operating in the peptide drug conjugates are Novartis AG, Oncopeptides AB, Cybrexa Therapeutics, Avacta Therapeutics, ProteinQure, Theratechnologies Inc., CBP, Soricimed Biopharma, NMS Group S.p.A., Mainline Scientific LLC., Bicycle Therapeutics, and others.

5. Which region has the highest share in the global peptide drug conjugates market?

• North America region is anticipated to dominate the overall peptide drug conjugates market due to the rising cases of cancers in the U.S. Additionally, the increase in collaborations among key players for peptide drug conjugates development, and growing investments in the domain of PDCs are further propelling the overall market of PDCs across the region.

Table of Contents

1. Peptide Drug Conjugates Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Peptide Drug Conjugates Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Peptide Drug Conjugates Market Key Factors Analysis

• 5.1. Peptide Drug Conjugates Market Drivers
  • 5.1.1. Rising cases of cancer worldwide
  • 5.1.2. Growing adoption of peptide drug therapeutics owing to superior treatment outcomes and enhanced efficacy
  • 5.1.3. Increase in strategic collaborations and product development activities in the domain of peptide drug conjugates.
• 5.2. Peptide Drug Conjugates Market Restraints and Challenges
  • 5.2.1. Limited therapeutic potential on solid tumors and low oral bioavailability
  • 5.2.2. High manufacturing cost and complexity
• 5.3. Peptide Drug Conjugates Market Opportunities
  • 5.3.1. The presence of a robust drug portfolio in the pipeline for peptide drug conjugates

6. Peptide Drug Conjugates Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Peptide Drug Conjugates Market Assessment

• 7.1. By Product
  • 7.1.1. Lutathera (lutetium Lu 177 dotatate)
  • 7.1.2. Pepaxti (Melphalan flufenamide)
  • 7.1.3. Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
• 7.2. By Cancer Type
  • 7.2.1. Prostate Cancer
  • 7.2.2. Gastrointestinal Cancer
  • 7.2.3. Multiple Myeloma
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.1.2. Canada Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.1.3. Mexico Peptide Drug Conjugates Market Size in USD Million (2022-2032)
  • 7.3.2. Europe
    • 7.3.2.1. France Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.2.2. Germany Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.2.3. United Kingdom Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.2.4. Italy Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.2.5. Spain Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.2.6. Rest of Europe Peptide Drug Conjugates Market Size in USD Million (2022-2032)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.3.2. Japan Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.3.3. India Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.3.4. Australia Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.3.5. South Korea Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.3.6. Rest of Asia-Pacific Peptide Drug Conjugates Market Size in USD Million (2022-2032)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.4.2. Africa Peptide Drug Conjugates Market Size in USD Million (2022-2032)
    • 7.3.4.3. South America Peptide Drug Conjugates Market Size in USD Million (2022-2032)

8. Peptide Drug Conjugates Market Company and Product Profiles

• 8.1. Novartis AG
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Oncopeptides AB
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Cybrexa Therapeutics
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Avacta Therapeutics
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. ProteinQure
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Theratechnologies Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. CBP
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Soricimed Biopharma
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. NMS Group S.p.A.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Mainline Scientific LLC.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Bicycle Therapeutics
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us